Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium
Open Access
- 8 February 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 11 (6), 1424-1439
- https://doi.org/10.1158/2159-8290.cd-20-0564
Abstract
Analysis of data from the Leukemia Precision-based Therapy (LEAP) Consortium revealed that many pediatric patients with leukemia may have genetic aberrations targetable with existing therapies; clinical validation is awaited.All Related Versions
Funding Information
- Wong Family Fund for Translational Research (R35 CA210030)
- Wong Family Fund for Translational Research (K08 CA222684)
- Wong Family Fund for Translational Research (1K08CA184418)
- Wong Family Fund for Translational Research (1U01CA232486)
This publication has 58 references indexed in Scilit:
- OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CMLNew England Journal of Medicine, 2013
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemiaNature, 2012
- Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibitionProceedings of the National Academy of Sciences, 2009
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia GenomeNew England Journal of Medicine, 2009
- Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimeticJournal of Clinical Investigation, 2008
- Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19Leukemia, 2006
- Genomic approaches to hematologic malignanciesBlood, 2004
- FLT3 mutations in childhood acute lymphoblastic leukemiaBlood, 2004
- The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane DomainMolecular Cell, 2004
- Inhibition of FLT3 in MLLCancer Cell, 2003